Actively Recruiting
Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor
Led by St. Petersburg State Pavlov Medical University · Updated on 2025-11-20
60
Participants Needed
1
Research Sites
82 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Optimization of bendamustine-containg graft-versus-host disease (GVHD) prophylaxis to reduce the incidence of secondary haemophagocytic lymphohistiocytosis and GVHD
CONDITIONS
Official Title
Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with indication for allogeneic hematopoietic stem cell transplantation
- Patients with less than 10/10 HLA-matched related or unrelated donor available, matching at HLA-A, HLA-B, HLA-Cw, HLA-DRB1, and HLA-DQB1
- Use of peripheral blood stem cells or bone marrow as graft source
- Diagnosis of high-risk myeloid malignancies including acute myeloid leukemia, chronic myeloid leukemia (Ph+), myelodysplastic syndromes, myeloproliferative neoplasms, chronic myelomonocytic leukemia, or unclassifiable myeloproliferative neoplasms
- High-risk disease defined by more than 5% of clonal blasts in bone marrow despite previous therapy, specific genetic mutations (such as -7 or complex karyotype, p53 mutation), treatment-related myelodysplastic syndrome, or second/subsequent allogeneic stem cell transplant after relapse
- No severe concurrent illness
You will not qualify if you...
- Patients with indication for allogeneic hematopoietic stem cell transplantation
- Patients with less than 10/10 HLA-matched related or unrelated donor available, matching at HLA-A, HLA-B, HLA-Cw, HLA-DRB1, and HLA-DQB1
- Use of peripheral blood stem cells or bone marrow as graft source
- Diagnosis of high-risk myeloid malignancies including acute myeloid leukemia, chronic myeloid leukemia (Ph+), myelodysplastic syndromes, myeloproliferative neoplasms, chronic myelomonocytic leukemia, or unclassifiable myeloproliferative neoplasms
- High-risk disease defined by more than 5% of clonal blasts in bone marrow despite previous therapy, specific genetic mutations (such as -7 or complex karyotype, p53 mutation), treatment-related myelodysplastic syndrome, or second/subsequent allogeneic stem cell transplant after relapse
- No severe concurrent illness
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Pavlov University
Saint Petersburg, Russia, 197022
Actively Recruiting
Research Team
A
Alexandr D Kulagin, MD, Prof
CONTACT
I
Ivan S Moiseev, MD, Prof.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here